🔎 Trials Near Me

Akèy › Myelom Miltip › Oregon › Portland

Etid klinik pou Myelom Miltip nan Portland, OR

13 etid pou Myelom Miltip ap chèche patisipan nan sit nan ak bò kote Portland (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.

Tèks ofisyèl etid la (Anglè)

Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →

A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

Ap rekriteFaz 3
  • Oregon Health And Science University, Portland
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07258511

Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment

Ap rekriteEtid obsèvasyon
  • OHSU Knight Cancer Institute, Portland
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT06784167

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

Ap rekriteFaz 2
  • Providence Health & Services, Portland
Laj 12 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT02693535

Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

Ap rekriteFaz 2
  • Oregon Health and Science University, Portland
Laj 18 ak plis · Tout sèks · Mizajou Sep 14, 2026 · NCT06297226

A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)

Ap rekriteFaz 1/2
  • Oregon Health and Science University /ID# 272282, Portland
Laj 18 ak plis · Tout sèks · Mizajou Sep 14, 2026 · NCT06953960

A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma

Ap rekriteFaz 1
  • Providence Portland Medical Center, Portland
Laj 18 ak plis · Tout sèks · Mizajou Aug 28, 2026 · NCT07075185

Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT

Ap rekriteFaz 3
  • Research Site, Portland
Laj 18 ak plis · Tout sèks · Mizajou Aug 14, 2026 · NCT07764978

Immuno-PRISM (PRecision Intervention Smoldering Myeloma)

Ap rekriteFaz 2
  • Oregon Health & Science University, Portland
Laj 18 ak plis · Tout sèks · Mizajou Jul 16, 2026 · NCT05469893

Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment

Ap rekriteFaz 3
  • Providence Portland Medical Center, Portland
  • Providence Saint Vincent Medical Center, Portland
  • Providence Willamette Falls Medical Center, Oregon City · 12 mi lwen
Tout laj · Tout sèks · Mizajou Jun 10, 2026 · NCT05561387

Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma

Ap rekriteFaz 1/2
  • Oregon Health and Science University (OHSU) Marquam Hill Campus, Portland
Laj 18 ak plis · Tout sèks · Mizajou Apr 20, 2026 · NCT03761108

cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

Ap rekriteEtid obsèvasyonVolontè an sante akeyi
  • Oregon Health Sciences University, Portland
Laj 40 ak plis · Tout sèks · Mizajou Jan 20, 2026 · NCT05366881

Etid Myelom Miltip nan lòt vil

Lòt etid nan Portland

Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.